Abstract 10P
Background
As a result of a significant decrease in smoking prevalence in many countries, the overall incidence of head and neck squamous cell carcinoma (HNSCC) is declining. However, there is a growing recognition of an increased incidence of oral tongue squamous cell carcinoma (OTSCC) in non-smokers and non-drinkers (NSND) for reasons that are yet to be fully understood. OTSCC in NSND and smoker-drinker (SD) individuals have different molecular profiles, as well as distinct immune microenvironments, which may affect their susceptibility to targeted therapies and immunotherapy. The prognostic value of tumor-infiltrating lymphocytes (TILs) and tertiary lymphoid structures (TLS) in localized oral tongue squamous cell carcinoma (OTSCC) remains unclear. This study investigates the prognostic impact of TILs and TLS on recurrence in patients with surgically treated OTSCC in NSND.
Methods
A total of 100 patients with OTSCC underwent complete surgical resection at a single institution with a median follow-up of 35 months (IQR 12-60). TIL presence (minimal, moderate, heavy) and TLS maturation (aggregate, primary follicle, secondary follicle) were graded using brightfield H&E slides according to previously published criteria. The prognostic impact of TILs and TLS on survival was analyzed using multivariable Cox regression, adjusting for prognostic factors (tumor size, depth of invasion, grade, and surgical margin status). Multivariable logistic regression was used to evaluate these factors for associations with early recurrence (≤12 months).
Results
Heavy TIL presence was observed in 41% of cases, and TLS was present in 76%, of which 23% were mature. The presence of mature TLS was associated with reduced odds of early recurrence [OR 0.18, P=0.04], and the presence of heavy TILs was associated with improved overall survival (OS) [HR 0.26, P=0.02]. Tumors categorized as TIL-/TLS- were associated with significantly worse OS [HR 3.5, P=0.02] compared to tumors with heavy TILs or mature TLS.
Conclusions
TILs and mature TLS are independently associated with decreased rate of early recurrence for high-risk localized OTSCC. Further studies should validate these potential low-cost biomarkers.
Editorial acknowledgement
During the preparation of this work the author(s) used Chat GPT in order to checking grammar. After using this tool/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication.
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
22P - Extracellular vesicles as predictive biomarkers for chemoimmunotherapy in biliary tract cancer
Presenter: Michele Zanoni
Session: Poster Display session
Resources:
Abstract
23P - Non-small cell lung cancer DNA methylation profiles correlate with immune checkpoint inhibitor response
Presenter: Julia Berger
Session: Poster Display session
Resources:
Abstract
24P - Blood DNA methylation profiles in NSCLC patients treated with immune checkpoint inhibitors
Presenter: Markus Kleinberger
Session: Poster Display session
Resources:
Abstract
25P - Circulating tumor DNA is predictive of overall survival in patients with metastatic uveal melanoma
Presenter: Egle Ramelyte
Session: Poster Display session
Resources:
Abstract
26P - Liquid biopsy-based percision immunotherapy: CCAT1 and HEIH lncRNAs identify young breast cancer patients likely to respond to PD-L1 blockade
Presenter: Rana Youness
Session: Poster Display session
Resources:
Abstract
27P - Single cell RNA sequencing (scRNAseq) analysis of peripheral immune cell populations from patients treated with anti-PD1 with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
Presenter: Séverine Carlier
Session: Poster Display session
Resources:
Abstract
28P - Circulating biomarkers in non-small cell lung cancer patients treated with immune checkpoint inhibitors
Presenter: Paola Ulivi
Session: Poster Display session
Resources:
Abstract
29P - Prognostic value of systemic inflammatory index and platelet-to-lymphocyte ratio in muscle-invasive bladder cancer patients treated with neoadjuvant chemo-immunotherapy in the AURA trial
Presenter: Jeremy Blanc
Session: Poster Display session
Resources:
Abstract
30P - The prognostic value of low density neutrophils in breast cancer: Implications for therapeutic strategies
Presenter: Telma Martins
Session: Poster Display session
Resources:
Abstract
31P - Peripheral-blood Immune-predictors of pathological complete response in patients with triple-negative breast cancer undergoing neoadjuvant chemo-immunotherapy
Presenter: Celeste Santoro
Session: Poster Display session
Resources:
Abstract